Target molecules and their inhibitors that control the survival and reactivation of disseminated tumor cells (cancer metastasis-initiating cells).
Inserting 50-nucleotide synthetic repeat sequences into the 5’UTR significantly enhances mRNA translation, achieving up to 10-fold increases in protein expression in both cells and animals
Discovery of a new mechanism of hypertension induction and proposal for drug discovery collaboration based on the mechanism.
New therapeutic targets and therapeutic agents for trauma-induced heterotopic ossification in FOP patients.
D35LNPs stimulate TLR9 and significantly induce the release of IFN-α from plasmacytoid dendritic cells, thereby strongly enhancing systemic immunity
siRNAs containing innovative artificial nucleic acids selectively suppress mRNAs containing abnormally expanded CAG repeats
Improved S-TuD (Synthetic Tough Decoy) RNA nucleic acid that inhibits miR-200 family, which is highly expressed in mammary cancer, colon cancer, endometrial cancer, ovarian cancer, etc.
Using vesicles derived from the cell membrane of target bacteria allows for highly species-specific treatment
Identification of prostaglandin receptors involved in the pathogenesis of endometriosis. [Collaborative Research Proposal]
RNA-binding molecules, such as antisense oligonucleotides and small molecules, facilitate back-splicing progression and augment circular RNA
Therapeutic target molecules and antisense oligonucleic acid (ASO) therapeutic agents for autosomal dominant polycystic kidney disease (ADPKD).
Splice-switching antisense oligonucleotides (SSOs) targeting the α-synuclein (SNCA) gene suppress α-synuclein (α-Syn) aggregation.
ASO-4733: Optimized Anti-SYT13 antisense oligonucleotides
Newly designed KK-(EK)4-lipid having near neutral charge enhances intracellular translocation of drug carrier
Molecular targeted drugs targeting the NIK associated with the differentiation factor from hepatocytes to cholangiocarcinoma
Also useful as a companion diagnostics (CDx) for immune checkpoint inhibitors (ICIs).
Overcoming the challenges of mRNA medicine by improving translation efficiency
Antisense oligonucleotide (ASO) therapy for two independent targets, GREB1 and ARL4C genes.